Cancer drug development: The missing links

Area of Science:

• Drug development
• Clinical trials
• Pharmaceutical research

Background:

• The success rate for drugs entering phase 1 clinical trials is notably low.
• Pre-clinical studies may not accurately predict efficacy for human diseases, contributing to high failure rates.
• The cost of research and development for an average FDA-approved drug has significantly increased over time.

Purpose of the Study:

• To investigate the reasons behind the low success rate of cancer drugs in clinical trials.
• To understand the inadequacy of pre-clinical studies in predicting drug response in humans.
• To analyze the escalating costs of drug development and their potential impact on drug pricing and testing.

Main Methods:

• Analysis of historical data on drug development costs (e.g., Tufts Center for the Study of Drug Development data from 1975 to 2005).
• Examination of the relationship between drug development expenses, drug pricing, and market sales.
• Review of factors contributing to high drug development costs, including patient response variability.

Main Results:

• The cost of developing an average FDA-approved drug increased from $100 million in 1975 to $1.3 billion by 2005.
• There is no clear correlation between the high cost of drug development and the actual sales revenue of the drug.
• Patient response variability is a significant factor contributing to the need for extensive and costly clinical trials.

Conclusions:

• The high failure rate of cancer drugs suggests a critical gap between pre-clinical research and human disease response.
• Escalating drug development costs, driven partly by the need to test in large patient populations due to variable responses, contribute to higher product prices.
• Further research is needed to improve pre-clinical models and identify patient subgroups likely to respond to specific drugs, thereby increasing success rates and potentially reducing costs.